present invention relates to compounds of formula I, or a pharmaceutically active salt, a racemic mixture, enantiomers, relates to an optical isomer or a tautomeric form: formula I where the, R 1 is hydroxy or NRR and R and R is or independently represent hydrogen, lower alkyl or cycloalkyl each other, may form a heterocyclic ring with the alkyl N- atom to which they are attached R 2 is hydrogen, lower alkyl, lower alkoxy, halogen, lower alkyl substituted by halogen, cyano, lower alkoxy substituted by halogen, or S (O) 2 - lower alkyl R 3 is optionally substituted by halogen, lower alkyl or - (CH 2 ) m - aryl Or - (CH 2 ) m - cycloalkyl R 4 and R 5 is independently represent hydrogen, lower alkyl substituted by halogen, - (CR 2 ) m - aryl or - (CR 2 ) m - heteroaryl (wherein the ring is optionally substituted by halogen, lower alkyl, lower alkyl substituted by halogen, cyano, hydroxy, and NRR one or more substituents selected from halogen substituted or substituted with a lower alkoxy may be), optionally substituted with hydroxy or aryl - (CR 2 ) m - cycloalkyl, or optionally, = O or - (CR 2 ) m - or a heterocyclic ring substituted alkyl, aryl, R 4 and R 5 N- atom to which they are attached and, optionally, lower alkyl, aryl or with halogen-substituted to form a heterocyclic ring system substituted with aryl R can be independently hydrogen, lower alkyl, or lower alkyl substituted by hydroxy to each other n is 1 or 2. m is 0, 1 or 2. The compounds of the present invention depression, pain, psychosis, Parkinsons disease, schizophrenia, anxiety and attention deficit hyperactivity NK3 receptor antagonists were found to be high performance in the treatment of behavioral disorders (ADHD).본 발명은 하기 화학식 I의 화합물, 또는 그의 약학적으로 활성인 염, 라세미 혼합물, 거울상 이성질체, 광학 이성질체 또는 토토머 형태에 관한 것이다:화학식 I상기 식에서,R1은 하이드록시 또는 NRR이고R 및 R은 서로 독립적으로 수소, 저급 알킬 또는 사이클로알킬이거나, 이들이 부착된 N-원자와 함께 헤테로알킬 고리를 형성할 수 있고 R2는 수소, 저급 알킬, 저급 알콕시, 할로겐, 할로겐으로 치환된 저급 알킬, 할로겐으로 치환된 저급
